|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Indoleamine 2,3-dioxygenase 1 (IDO1) plays a vital role in tumor immune escape and has emerged as a promising target for cancer immunotherapy.
|
31785855 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The notion of inhibiting IDO1 using small-molecule inhibitors elicited high hopes of a positive impact in the field of immuno-oncology, by restoring anti-tumour immune responses and synergising with other immunotherapies such as immune checkpoint inhibition.
|
31819194 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Although increased tumor expression of IDO is associated with resistance to antibody therapy against programed cell death-1 (anti-PD1), co-administration of anti-PD1 with shIDO-ST did not provide additional tumor growth control in either model of colorectal cancer.
|
30824815 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Similarly, IDO1 protein expression was significantly increased in the tumor glands of PTEN-deficient PCa (P < 0.0001).
|
30999388 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Additionally, H<sub>2</sub>S donors effectively restricted the tumor development in H22 HCC-bearing mice via downregulating IDO1 expression, inducing T-effector cells and inhibiting MDSCs.
|
30777103 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Gene expression analysis in PDAC tumors (n = 63) showed a positive correlation between the expression of NOS2 and the tryptophan/kynurenine pathway genes, including indoleamine-2,3-dioxygenase 1 (IDO1) and several aryl hydrocarbon receptor (AHR)-target genes including NFE2L2 (NRF2), SERPINB2, IL1b, IL6 and IL8, which are implicated in pancreatic cancer.
|
31609478 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Having a critical role in tumor immune escape by decreasing Trp and increasing Kyn levels in the microenvironment, IDO1 was one of the first targets for small molecules drug discovery in the field of immuno-oncology.
|
30933897 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, a decrease in the numbers of regulatory T cells in the tumor was observed in mice that were treated with the IDO1-silenced DC.
|
31383907 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Monocyte education by tumor cell-conditioned medium induced their growth and reprogrammed them towards immunosuppressive tumor-associated macrophages that expressed IDO and PD-L1 and secreted IL-10, CCL17 and TGF-β.
|
30309853 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CXCR4 antagonism in combination with IDO1 inhibition weakens immune suppression and inhibits tumor growth in mouse breast cancer bone metastases.
|
31388305 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Third, as a highly selective IDO1 inhibitor, epacadostat was advanced aggressively despite preclinical genetic evidence of tumors bypassing IDO1 blockade.
|
30203227 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Indoleamine 2,3-dioxygenase 1 (IDO1) is a key enzyme in tryptophan metabolism and plays an important role in tumor cell immunosuppression and angiogenesis.
|
30594037 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Like several other barriers in the TME, such as the PD-1/PDL-1 axis, CTLA-4, and indoleamine 2,3-dioxygenase (IDO-1), adenosine plays important physiologic roles, but has been co-opted by tumors to promote their growth and impair immunity.
|
31244820 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Although both IL17<sup>Low</sup> and IL17<sup>High</sup> immunoreactive MMRp colorectal cancers are associated with intratumor correlates of adaptive immunosuppression (CD8/IFNγ and PD-L1/IDO1 colocalization), only IL17<sup>Low</sup> MMRp tumors (3/14) have a tumor immune microenvironment (T<i>i</i>ME) that resembles the T<i>i</i>ME in primary colon tumors of patients with mCRC responsive to anti-PD-1 treatment.
|
31061070 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Membrane PD-L2 expression and cytoplasmic IDO1 expression were defined by tumor proportion score (TPS); samples with TPS < 1% were considered negative.
|
31163080 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
It suggests that these immune checkpoint receptors and IDO could be considered as biomarkers to reflect immune status in the tumor microenvironment during nimotuzumab therapy.
|
31132187 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our study supports the combination of IDO1 inhibitor and vaccine therapy; however, it does not support the combination of IDO1 inhibitor and anti-PD-1/PD-L1 antibody for T cell-inflamed tumors such as PDACs treated with vaccine therapy.
|
30747725 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
IDO1 (Indoleamine 2,3-dioxygenase 1) inhibits host anti-tumor immune response by exhausting tryptophan in tumor microenvironment, but the pathogenic mechanisms of IDO1 in gastric cancer (GC) cells need to be further explored.
|
31315643 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Of the tumour specimens evaluable for immunohistochemistry, 100% showed CD8+ lymphocyte infiltration and 93.4% stained positive for IDO1.
|
30671614 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Indoleamine 2,3-dioxygenase 1 (IDO1) is an enzyme that participates in tumor immune escape primarily by catalyzing tryptophan to L-kynurenine.
|
31324754 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Although high expression levels of IDO1 and WARS were associated with poor prognosis in p53-aberrant, p53-wildtype, and all cancers combined, WARS expression was associated with better prognosis in MSI tumors.
|
31033497 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The only marker found to have a robust association with outcome was tumor IDO1.
|
30755500 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, CAI also stimulated IDO1-Kyn metabolic circuitry in the tumor microenvironment and facilitated tumor cell immune evasion.
|
31511064 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This suggests that apoptotic and necrotic tumor cells, via efferocytosis and IDO1, respectively, promote tumor 'homeostasis' and progression.
|
30413412 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We performed a systematic review of studies reporting on such F-18-labeled tryptophan tracers to summarize and compare their biological characteristics and their potential for tumor imaging, with a particular focus on key enzymes of the kynurenine pathway (indoleamine 2,3-dioxygenase [IDO] and tryptophan 2,3-dioxygenase [TDO]), which play an important role in tumoral immune resistance.
|
31512038 |
2019 |